BIO vs MTVA · rev $2.58B vs $8.8M cap
BIO (BIO) versus MetaVia Inc. (MTVA) — a side-by-side from cached financials, not a winner call.
BIO (BIO) common stock.
MetaVia Inc. (MTVA) is a biotechnology company listed on NASDAQ.
Latest reported BIO revenue for 2025-12-31 was $2.58B. Net income was $759.9M. Revenue was up 0.7% from 2024-12-31 to 2025-12-31. BIO currently screens at market cap $0.
MTVA does not have a complete income-statement cache yet.
BIO currently screens at market cap $0. MTVA currently screens at market cap $8.8M.
Not investment advice. Open the BIO and MTVA stock pages for the full models.
Not investment advice.